CMS Electronic Speech Aids Coverage Policy Update (NCD 237): What Billing Teams Need to Know

CMS has modified its National Coverage Determination for electronic speech aids under NCD 237, with an effective date of March 12, 2026. This policy governs Medicare Part B coverage of electrolarynx devices and oral amplification aids for patients who have undergone laryngectomy or have a permanently inoperative larynx. If your practice serves head and neck surgery, oncology, or speech-language pathology patients, this update belongs on your billing team's radar now.

What CMS NCD 237 Covers for Electronic Speech Aids

The Centers for Medicare & Medicaid Services classifies electronic speech aids as prosthetic devices under Medicare Part B. That classification matters for billing—it determines the benefit category, cost-sharing structure, and the medical necessity standard your documentation must satisfy.

NCD 237 recognizes two distinct device types:

• Throat-contact (transcervical) devices — A vibrating head is placed against the patient's throat to produce voice. These are the more commonly recognized "electrolarynx" style devices.
• Oral tube (intraoral) devices — A tube is inserted into the mouth to amplify sound waves. These are typically less expensive and may be the only functional option for certain post-surgical patients.

The device type distinction isn't just clinical—it has real billing and medical necessity documentation implications, which we'll cover below.

CMS Coverage Criteria: Who Qualifies Under NCD 237

Coverage under Part B is limited to patients who meet one of two conditions:

Both conditions represent permanent loss of natural voice production. Medicare is explicit that this is not a temporary-use benefit—the "permanently inoperative" language rules out coverage for transient conditions like acute laryngitis or short-term intubation complications.

There is no ambiguity here: if the patient does not meet one of these two criteria, the claim will not survive a coverage review. Make sure your documentation clearly establishes which condition applies and that it is reflected in the referring provider's order.

Device Selection and Medical Necessity: Why the Surgery Type Matters

NCD 237 includes an important clinical distinction that directly affects medical necessity documentation. Patients who have undergone radical neck surgery and/or extensive radiation to the anterior neck will generally be unable to use a standard throat-contact device effectively—or at all.

For these patients, CMS acknowledges that two options exist:

• The oral tube model (typically the baseline option), or
• A more sensitive, higher-cost throat-contact device designed to work even when cervical tissue is compromised

This matters for billing because if a supplier or provider furnishes a premium throat-contact device to a post-radiation patient, the medical record needs to clearly explain why the standard device is not appropriate. "Patient had radical neck surgery with anterior radiation" is the documentation anchor that supports the upgraded device. Without that link in the clinical record, a more expensive device claim is vulnerable to denial or audit.

Benefit Category: Part B Prosthetic Devices

Because electronic speech aids fall under the prosthetic devices benefit category, claims are subject to the standard Part B prosthetic device rules:

• 80/20 cost sharing applies (Medicare pays 80% of the approved amount after the deductible)
• Suppliers must be enrolled Medicare DMEPOS suppliers when furnishing these items
• The order must come from a treating physician and document the covered diagnosis
• Claims processing follows the guidance in the Medicare Benefit Policy Manual, Chapter 15

If your practice is billing professional services related to evaluation and fitting rather than supplying the device itself, confirm that your billing pathway aligns with the prosthetics framework rather than a procedure-based approach.

Affected Codes

This policy does not list specific HCPCS or CPT codes within the NCD 237 policy document itself. Billing teams should reference the Medicare DMEPOS fee schedule and the Medicare Benefit Policy Manual, Chapter 15 to identify the applicable HCPCS Level II codes for electrolarynx and oral speech aid devices. Submitting without verifying the current HCPCS codes against your MAC's local guidance is a common source of claim errors for this category.

No codes are enumerated in the current NCD 237 policy document. Do not rely on internally circulated code lists that have not been validated against the current CMS DMEPOS fee schedule.

What Your Billing Team Should Do